• linkedin
  • Increase Font
  • Sharebar

    PCa active surveillance trends revealed in ‘real-world’ study

    Nearly three-quarters of men with very low-risk prostate cancer underwent active surveillance as a primary therapy in a study presented at the LUGPA annual meeting in Chicago.

    The study sought to determine “real-world” practice patterns regarding the initial management of men with newly diagnosed prostate cancer and with a 3-year follow-up on the cohort undergoing active surveillance in community urology practices.

    The study results were presented by Jeremy Shelton, MD, MSHS, of Skyline Urology, Los Angeles and UCLA’s David Geffen School of Medicine, Los Angeles.

    Funded by an unrestricted grant from Genomic Health, the study cohort included 2,142 cases of men with very low-, low-, and intermediate-risk prostate cancer and 3.4-year follow-up on 546 men on active surveillance.

    According to Dr. Shelton, major strengths of the study include its “setting in a geographically distributed collection of practices as well as rich clinical and operational details that allow researchers a window into not just treatment trends, but their appropriateness as well.”

    Key findings include the utilization of active surveillance as a primary therapy by 72% of men with very low-risk disease, and equal and appropriate utilization of surgery and radiotherapy when curative therapy was sought, with no evidence that recent trends in consolidated ownership of prostate cancer-specific treatment modalities had led to overutilization. Some variation in management was seen by practice, consistent with other studies and a likely target of future research efforts.

    Next: Nearly 90% of men continued their care with their diagnosing practice.

    Bob Gatty
    Bob Gatty, a former congressional aide, covers news from Washington for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available